Athersys up as FDA grants clinical meeting to discuss stroke therapy study

Athersys

14/02/2023 15:49

** Shares of drug developer Athersys Inc  ATHX.O  rise 2.3%
to $1.81 
    ** Co says the U.S. Food & Drug Administration (FDA) has
granted a clinical Type B meeting to discuss proposed
modifications to an ongoing late-stage study testing its cell
therapy, MultiStem, in the treatment of ischemic stroke
    ** FDA meeting is scheduled for late March - ATHX
    ** Including session's move, stock has fallen ~91.6% in the
past 12 months
 (Reporting by Mariam E Sunny)
 ((Mariam.ESunny@thomsonreuters.com;))